Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusFRA:AJ8 -3.94%48 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus rates FRA:AJ8 with a GF Score™ of 48/100 and a GF Value™ of €3.22 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 149 Biotechnology companies, Agenus ranks worse than 671140.27% on this metric.
Agenus's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Agenus's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:AJ8's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Agenus 5-Year Yield-on-Cost % Related Terms
FRA:AJ8 vs FULC, IRD, TTRX: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Agenus's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Agenus's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Agenus is calculated as
Agenus (FRA:AJ8) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #999999 out of 149 companies in the Biotechnology industry.
Is Agenus' 5-Year Yield-on-Cost % too high?
Agenus' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Agenus ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agenus has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' 5-Year Yield-on-Cost % compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Agenus in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Agenus and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (FRA:AJ8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.22, compared to a current price of €6.10 — trading 89.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Agenus' overall GF Score™ is 48/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Agenus (FRA:AJ8), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (FRA:AJ8) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for FRA:AJ8:
5-Year Yield-on-Cost %: 0.00
GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
48GF Score
Get the complete analysis for FRA:AJ8
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ8 has been successfully added to your 
